22 hasil untuk "Mathieu Le Gars"
Menampilkan 1–20 · 0,94 detik · RSS
-
Artikel Jurnal
CytoGLMM: conditional differential analysis for flow and mass cytometry experiments
Abstract Background Flow and mass cytometry are important modern immunology tools for measuring expression levels of multiple proteins on single cells. The goal is to better understand the mechanisms of responses on a single cell basis by studying differential expression of proteins. Most current…
-
Artikel Jurnal
Early transcriptional responses following Ad26.COV2.S vaccination in individuals with prior SARS-CoV-2 infectionResearch in context
Summary: Background: Ad26.COV2.S is a recombinant, replication-incompetent human adenovirus serotype 26 (Ad26) vectored vaccine encoding a full-length SARS-CoV-2 spike protein in a prefusion-stabilised conformation. The genes and pathways which are differentially regulated following vaccination…
-
Artikel Jurnal
Mechanistic modeling projections of antibody persistence after homologous booster regimens of COVID‐19 vaccine Ad26.COV2.S in humans
Abstract Mechanistic model‐based simulations can be deployed to project the persistence of humoral immune response following vaccination. We used this approach to project the antibody persistence through 24 months from the data pooled across five clinical trials in severe acute respiratory syndrome…
-
Artikel Jurnal
Pregnancy-Induced Alterations in NK Cell Phenotype and Function
Pregnant women are particularly susceptible to complications of influenza A virus infection, which may result from pregnancy-induced changes in the function of immune cells, including natural killer (NK) cells. To better understand NK cell function during pregnancy, we assessed the ability of the…
-
Artikel Jurnal
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial
We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 1010 viral particles [vp]) in healthy adolescents aged 12–17 years. Participants were randomly assigned to receive…
-
Artikel Jurnal
Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
To evaluate the 8-month durability of humoral and cellular immune responses after Ad26.COV2.S Vaccination
-
Artikel Jurnal
Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy
COVID-19 during pregnancy can be associated with adverse pregnancy and infant outcomes. We assessed the safety, reactogenicity, and immunogenicity of maternal vaccination with Ad26.COV2.S COVID-19 vaccine and monitored serum and breast milk antibody levels in mothers and infants until 6 months…
-
Artikel Jurnal
An Ad26‐MVA‐BN‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections
Abstract Objectives To develop a therapeutic human papillomavirus (HPV) vaccine capable of intercepting HPV‐related cervical disease to reduce the number of new cancer cases and associated deaths. Methods We previously reported that replication‐deficient adenovirus type 26 and 35‐based vectors…
-
Artikel Jurnal Teks lengkap
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial
Background: This study aimed to support the end-of-shelf life specification (2.5 × 1010 virus particles [vp]) for the standard Ad26.COV2.S dose (5 × 1010 vp). Methods: This randomized, double-blind Phase 3 study evaluated immunogenicity, reactogenicity, and safety of several Ad26.COV2.S dose levels…
-
Artikel Jurnal
Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6® cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age
An inactivated poliovirus vaccine candidate using Sabin strains (sIPV) grown on the PER.C6® cell line was assessed in infants after demonstrated immunogenicity and safety in adults. The study recruited 300 infants who were randomized (1:1:1:1) to receive one of 3 dose levels of sIPV or a…
-
Artikel Jurnal
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trialResearch in context
Summary: Background: While vaccine-induced SARS-CoV-2 antibodies provide partial protection against COVID-19, a significant question remains regarding the role of vaccine-induced T cells in combating COVID-19. The purpose of this study is to investigate whether signatures of the T-cell response…
-
Artikel Jurnal
B cell somatic hypermutation following COVID-19 vaccination with Ad26.COV2.S
Summary: The viral vector-based COVID-19 vaccine Ad26.COV2.S has been recommended by the WHO since 2021 and has been administered to over 200 million people. Prior studies have shown that Ad26.COV2.S induces durable neutralizing antibodies (NAbs) that increase in coverage of variants over time…
-
Artikel Jurnal
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trialResearch in context
Summary: Background: Vaccine co-administration can increase vaccination coverage. We assessed the safety, reactogenicity, and immunogenicity of concomitant administration of Ad26.COV2.S COVID-19 vaccine with seasonal influenza vaccines. Methods: This non-inferiority, Phase 3, randomised…
-
Artikel Jurnal
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
BACKGROUND: The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a prefusion-stabilized conformation. METHODS: viral particles) or placebo. The primary end…
-
Artikel Jurnal Teks lengkap
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinant, replication-incompetent adenovirus serotype 26…
-
Artikel Jurnal Teks lengkap
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
BACKGROUND: The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS: viral particles) or placebo. The primary end points were vaccine efficacy against moderate to…
-
Artikel Jurnal Teks lengkap
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Abstract The Ad26.COV2.S vaccine 1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies 1 . However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern remains…
-
Artikel Jurnal
SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
Several COVID-19 vaccines have received emergency approval, but durability of protection is unclear. Here, the authors describe correlates of protection (CoP) for the Ad26.COV2.S vaccine in rhesus macaques and report that CoP predict the protection observed 6 months post vaccination.
-
Artikel Jurnal Teks lengkap
Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
Importance: Control of the global COVID-19 pandemic will require the development and deployment of safe and effective vaccines. Objective: To evaluate the immunogenicity of the Ad26.COV2.S vaccine (Janssen/Johnson & Johnson) in humans, including the kinetics, magnitude, and phenotype of SARS-CoV-2…
-
Artikel Jurnal
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters
Abstract SARS-CoV-2 Spike-specific binding and neutralizing antibodies, elicited either by natural infection or vaccination, have emerged as potential correlates of protection. An important question, however, is whether vaccine-elicited antibodies in humans provide direct, functional protection…